Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffit Hassan

Showing results (71-80 of 150) with videos related to

Pageof 15
Sort By:
Clinical and Translational Medicine|November 16, 2024
Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomasSameer Mir, Abhilash Venugopalan, Jingli Zhang, et al.
Science Advances|May 2, 2025
Robust differentiation of NK cells from MSLN.CAR-IL-15-engineered human iPSCs with enhanced antitumor efficacy against solid tumorsQun Jiang, Weiming Yu, James Ma, et al.
Cancer Immunology, Immunotherapy : CII|January 22, 2010
Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxinRobert Sarnovsky, Tara Tendler, Matheusz Makowski, et al.
Plos One|February 10, 2011
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapyXinran Xiang, Yen Phung, Mingqian Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2010
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancersRaffit Hassan, Steven J Cohen, Martin Phillips, et al.
Clinical Genitourinary Cancer|June 14, 2017
Clinical Features and Outcomes of Tunica Vaginalis Mesothelioma: A Case Series From the National Institutes of HealthJulie Y An, David Kim, Sally Tanakchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISAMasanori Onda, Mark Willingham, Satoshi Nagata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2011
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hostsMiriam E Mossoba, Masanori Onda, Justin Taylor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing miceYuJian Zhang, Laiman Xiang, Raffit Hassan, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 20, 2016
Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for ImmunotherapyPeter B Illei, Christine Alewine, Marianna Zahurak, et al.
Pageof 15

Showing results (71-80 of 150) with videos related to

Sort By:
Pageof 15
Clinical and Translational Medicine|November 16, 2024
Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomasSameer Mir, Abhilash Venugopalan, Jingli Zhang, et al.
Science Advances|May 2, 2025
Robust differentiation of NK cells from MSLN.CAR-IL-15-engineered human iPSCs with enhanced antitumor efficacy against solid tumorsQun Jiang, Weiming Yu, James Ma, et al.
Cancer Immunology, Immunotherapy : CII|January 22, 2010
Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxinRobert Sarnovsky, Tara Tendler, Matheusz Makowski, et al.
Plos One|February 10, 2011
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapyXinran Xiang, Yen Phung, Mingqian Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2010
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancersRaffit Hassan, Steven J Cohen, Martin Phillips, et al.
Clinical Genitourinary Cancer|June 14, 2017
Clinical Features and Outcomes of Tunica Vaginalis Mesothelioma: A Case Series From the National Institutes of HealthJulie Y An, David Kim, Sally Tanakchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISAMasanori Onda, Mark Willingham, Satoshi Nagata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2011
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hostsMiriam E Mossoba, Masanori Onda, Justin Taylor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing miceYuJian Zhang, Laiman Xiang, Raffit Hassan, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 20, 2016
Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for ImmunotherapyPeter B Illei, Christine Alewine, Marianna Zahurak, et al.
Pageof 15